Exyte increases order intake, sales and profitability

  • Order intake up more than 25% year-on-year, marking a new 9M-raised with 6.5 billion euros
  • Sales volume increased by almost 60% to 5.3 billion euros
  • Strong sales growth in all three business segments
  • Adjusted EBIT increased by 73% to EUR 308 million; Adjusted EBITDA up 70% to €340 million
  • Acquisition of Airgard Inc., strengthening the strategic product portfolio of the Technology and Services business
  • New employer brand to attract new talent

STUTTGART, Germany, November 9, 2022 /PRNewswire/ — Exyte GmbH (Exyte), a global leader in the design, engineering and delivery of high-tech facilities, continues its strong performance in the first nine months of fiscal 2022 by making successful progress on its accelerated growth trajectory, its “Pathway to Ten”.

In the first nine months of 2022, Exyte saw an almost 60% year-over-year sales increase. Sales reached a record level of 5.3 billion euros (9M/2021: 3.4 billion euros) thanks to major projects in all sectors of activity, in particular in the APAC and EMEA regions. Both regions also contributed strongly to the order intake. From January to September, order intake reached 6.5 billion euros (9M/2021: 5.1 billion euros), an increase of more than 25% compared to the previous year.

With an adjusted EBITDA of 340 million euros (9M/2021: €200 million) and adjusted EBIT of €308 million (9M/2021: 178 million euros) Exyte has further improved its profitability. The adjusted EBITDA margin was 6.4% (9M/2021: 5.9%), the adjusted EBIT margin reached 5.8% (9M/2021: 5.3%), both increasing by 0.5% over one year.

“Our positive and sustained business development underscores our strong strategic position. The industries we serve continue to invest unchanged. global megatrends that will continue to unfold despite short-term economic turbulence,” says Dr. Wolfgang Büchele, CEO of Exyte.

Positive outlook despite current economic developments

“Exyte achieves its Pathway to Ten. Our revenue target of around €7 billion in 2022 brings us closer to our goal of reaching €10 billion in revenue in 2027. With Completed projects and an order book of EUR 8.2 billion, we are well positioned for future profitable growth.Despite continuing economic uncertainties, we see a sustainable positive development for Exyte,” says Peter Schönhofer, Chief Financial Officer “However, we are closely monitoring developments and their potential impact on our business and taking countermeasures as necessary.”

Exyte confirms the positive outlook for the end of the year. Consistent with an increase in sales, an increase in Adjusted EBITDA and Adjusted EBIT respectively is expected. For 2022, the company expects an adjusted EBITDA of around 450 million euros, respectively an adjusted EBIT above 400 million euros.

Growth in all business segments, Biopharma & Life Sciences and Data Centers with impressive sales development

In the first nine months of 2022, all three business segments acquired significant new projects across all regions. With a sales share of approximately 87% of total group sales, the business segment State-of-the-art facilities recorded an increase in its turnover of approximately 55% to 4.6 billion euros (9M/2021: €3.0 billion). Driven by the continued positive development in the semiconductor industry, incoming orders increased by almost a quarter to reach 5.5 billion euros (9M/2021: €4.5 billion). Battery cell manufacturers also benefit from Exyte’s expertise in clean and dry rooms. Exyte sees new sales opportunities in this sector in the coming years, as so-called gigafabs for the production of battery cells and batteries are planned around the world.

Biopharma & Life Sciences almost doubled its sales in the first nine months. Segment sales reached 477 million euros (9M/2021: 247 million euros) due to major projects in Singapore and Malaysia. Biopharma & Life Sciences represents 9.0% of the group’s total sales (9M/2021: 7.3%). Order intake reached 477 million euros (9M/2021: €384 million). In Germany, Exyte is building an mRNA Competence Center in Halle. Other biopharmaceutical projects for global pharmaceutical companies are in preparation. Exyte recently opened a new life sciences office in Cork, Ireland. The Irish pharmaceutical sector has grown rapidly in recent years. Exyte is planning significant investments in Ireland in projects ranging from biotechnology to filler finishing, active pharmaceutical ingredients, and cell and gene therapy.

The sales of the Data centers segment increased by 74% to reach 181 million euros (9M/2021: €104 million). Order intake increased by more than 130% to 409 million euros (9M/2021: €175 million). The business segment is currently implementing data center projects in Austria, Denmark, Germany, Israel, Malaysiaand Taiwanamong others.

Strategic growth of the Technology and Services segment

Exyte recently completed the acquisition of Airgard Inc., a US specialist in exhaust gas cleaning technology. Airgard’s wet scrubbers are used worldwide by key players in the semiconductor industry. The acquisition of Airgard strengthens Exyte’s position to support its customers with technical solutions for their exhaust gas management, also in light of the increasing standards that come with environmental, social and governance (ESG) regulations and requirements ).

This is the next acquisition by which Exyte strengthens its vertical integration strategy by strengthening its business in the field of mission-critical technologies and services. In 2021, Exyte acquired Critical Process Systems Group and incorporated it into the Technology & Services (T&S) business area. T&S consists of entities that provide cleanroom technology, installation services and critical equipment for its customers’ subsystems as well as off-site manufacturing (OSM). In the first nine months of 2022, Technology & Services nearly doubled its revenue to €555 million (9M/2021: 280 million euros) contributing approximately 10% to the group’s total revenue (9M/2021: 8.0%). Incoming orders more than doubled to reach 788 million euros (9M/2021: €336 million).

Progress on the “Pathway to Ten” – New employer brand

Targeted and strategic acquisitions are the cornerstone of Exyte’s future “Next Level” program. In this agenda, the company has defined several fields of action to achieve its “Pathway to Ten”. Another area of ​​action is to become the employer of choice for current and future employees. To that end, Exyte recently introduced a new employer brand that is the foundation for talent acquisition and recruitment globally. Approximately 15,000 employees are expected to work for Exyte in 2027, more than double the number in 2021. At the end of September 2022 Exyte employed nearly 9,000 people worldwide.

Financial key figures at a glance



To change

2022 vs. 2021

Order taking

€6.5 billion

€5.1 billion



€5.3 billion

3.4 billion euros


Adjusted EBITDA


€200 million


Adjusted EBITDA margin



+0.5 PP

Adjusted EBIT




Adjusted EBIT margin



+0.5 PP

*The percentage is calculated based on values ​​in millions.

For more details on the 9M-results 2022 please visit website exyte.net.

About Exyte

Exyte is a global leader in the design, engineering and delivery of ultra-clean, sustainable facilities for high-tech industries. With industry-leading expertise developed over more than a century, we serve customers in the sophisticated semiconductor, battery cell, pharmaceutical, biotechnology and data center markets. Exyte offers a full range of services from consulting to managing the implementation of turnkey solutions with the highest security and quality standards for our customers around the world. We are creating a better future by enabling key industries to improve the quality of modern life. In 2021, Exyte achieved sales of €4.9 billion with approximately 7,400 employees worldwide.


Rene Ziegler
Vice President Corporate Communications and Investor Relations
+49 711 88044606
+49 172 5838786
[email protected]

Logo: https://mma.prnewswire.com/media/1487100/Exyte_Logo.jpg



Comments are closed.